Publications

1. Nguyen A, Schaff HV, Crestanello JA, Luis SA, Halfdanarson TR, Connolly HM. Outcome of selective pulmonary valve management in patients undergoing surgery for carcinoid heart disease. J Thorac Cardiovasc Surg. 2025 May; 169 (5):e48-e49 Epub 2024 Apr 07
   View PubMed
2. Verschuur AVD, Chen L, Nieveen van Dijkum EJ, Luchini C, Halfdanarson TR, Hong SM, Singhi AD, Brosens LAA, Heaphy CM. Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective. Endocr Relat Cancer. 2025 May 1; 32 (5) Epub 2025 Apr 04
   View PubMed
3. Singh J, Gudmundsdottir H, Halfdanarson TR, Cleary SP, Kendrick ML, Truty MJ, Smoot RL, Nagorney DM, Vege SS. Pancreatic Neuroendocrine Tumors-A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution. Pancreas. 2025 May 1; 54 (5):e423-e429 Epub 2025 May 01
   View PubMed
4. Chandra S, Halfdanarson TR, Carlson EE, Rabe KG, Mahipal A, Majumder S, Bamlet WR, Horibe M, Tella SH, Shariq O, Carr RM, Cleary SP, Oberg AL, Antwi SO. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Endocr Relat Cancer. 2025 Apr 1; 32 (4) Epub 2025 Mar 01
   View PubMed
5. Gudmundsdottir H, Graham RP, Greipp PT, Habermann EB, Knudson RA, Brandt CA, Starlinger P, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Nagorney DM, Cleary SP, Halfdanarson TR. Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors. J Neuroendocrinol. 2025 Apr; 37 (4):e70003 Epub 2025 Feb 13
   View PubMed
6. Ledet CB, Sener U, Johnson DR, Ku K, Halfdanarson TR. Fruquintinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Multiply Metastatic Rectal Cancer. Clin Colorectal Cancer. 2025 Mar; 24 (1):98-100 Epub 2024 Sept 02
   View PubMed
7. Biesma NC, Graus MUJE, Cirkel GA, Besselink MG, de Groot JWB, Koerkamp BG, Herbschleb KH, Los M, Verdonk RC, Wilmink JW, Cervantes A, Valle JW, Valkenburg-van Iersel LBJ, Froeling FEM, Molenaar IQ, Daamen LA, de Vos-Geelen J, van Santvoort HC, Dutch Pancreatic Cancer Group. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Eur J Surg Oncol. 2025 Mar; 51 (3):109544 Epub 2024 Dec 12
   View PubMed
8. Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392 (7):653-665 Epub 2024 Sept 16
   View PubMed
9. Ammann M, Gudmundsdottir H, Antwi SKA, Santol J, Podrascanin V, Thiels CA, Warner SG, Truty MJ, Kendrick ML, Smoot RL, Cleary SP, Halfdanarson TR, Nagorney DM, Starlinger PP. Long-term outcome of cytoreductive hepatectomy in metastatic neuroendocrine neoplasia G3: A single center retrospective analysis. Eur J Surg Oncol. 2025 Feb 7; 51 (8):109678 Epub 2025 Feb 07
   View PubMed
10. Kibbi N, Owen JL, Worley B, Alam M, Extramammary Paget's Disease Guideline Study Group. Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype. J Am Acad Dermatol. 2025 Feb; 92 (2):261-268 Epub 2024 Oct 12
    View PubMed
11. Vorasoot N, Halfdanarson TR, Madigan NN, Dubey D, Thanarajasingam U, Zekeridou A. Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy. J Neuroimmunol. 2025 Jan 15; 398:578485 Epub 2024 Nov 12
    View PubMed
12. Tevaarwerk AJ, Karam D, Gatten CA, Harlos ES, Maurer MJ, Giridhar KV, Haddad TC, Alberts SR, Holton SJ, Stockham A, Leventakos K, Hubbard JM, Mansfield AS, Halfdanarson TR, Chen R, Jochum JA, Schwecke AS, Eiring RA, Carroll JL, Riaz IB, McWilliams RR, Galanis E, Mandrekar SJ. Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot. Cancer. 2025 Jan 1; 131 (1):e35304 Epub 2024 Apr 25
    View PubMed
13. Ammann M, Adjei Antwi SK, Gudmundsdottir H, Hackl H, Santol J, Guillot BE, Pappalettera G, Thiels CA, Warner SG, Truty MJ, Kendrick ML, Smoot RL, Nagorney DM, Cleary SP, Halfdanarson TR, Starlinger PP. Surgical and oncologic outcomes for liver resections of cystic neuroendocrine tumor liver metastasis. Eur J Surg Oncol. 2025 Jan; 51 (1):109464 Epub 2024 Nov 15
    View PubMed
14. Eslinger C, Seddighzadeh B, Yee C, Elsabbagh Z, Pai R, Hartley C, Starr J, Bekaii-Saab T, Halfdanarson TR, Sonbol MB. Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study. JCO Precis Oncol. 2025 Jan; 9:e2400450 Epub 2025 Jan 07
    View PubMed
15. Fuentes HE, Suleiman R, Graham RP, Villasboas Bisneto JC, Garcia JJ, Halfdanarson TR. Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience. Oncologist. 2024 Dec 25 [Epub ahead of print]
    View PubMed
16. Meng QH, Halfdanarson TR, Bornhorst JA, Jann H, Shaheen S, Shi RZ, Schwabe A, Stade K, Halperin DM. Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study. Clin Cancer Res. 2024 Dec 16; 30(24):5559-5567.
    View PubMed
17. Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14 [Epub ahead of print]
    View PubMed
18. Scalia IG, Sonbol MB, Farina JM, Pereyra M, Wang Y, Bekaii-Saab TS, Yang M, Connolly HM, Pellikka PA, Herrmann J, Halfdanarson TR, Starr JS, Luis SA, Arsanjani R, Ayoub C. Lutetium-177 DOTATATE Therapy and Cardiac Outcomes in Patients With Neuroendocrine Tumor and Cardiac Metastases. JACC CardioOncol. 2024 Dec; 6 (6):982-984 Epub 2024 Nov 12
    View PubMed
19. van Leeuwaarde RS, Halfdanarson TR, Sudhakar SM, Meijers RWJ, Folpe AL, Brosens LAA. Sarcomas arising in MEN1 patients: demonstrating LOH of the MEN1 locus and loss of menin expression. Fam Cancer. 2024 Nov 28; 24 (1):10
    View PubMed
20. Mohamed A, Trybula M, Asa SL, Halfdanarson TR, Sonbol M. Management of advanced high grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature. Endocr Relat Cancer. 2024 Oct 1; 31 (10) Epub 2024 Sept 21
    View PubMed
21. Baral B, Suleiman R, Fazer-Posorske CA, Ma DJ, McGarrah PW, Thome SD, Molina JR, Price KA, Halfdanarson TR, Fuentes HE. Advancing head and neck cancer management: Unveiling the diagnostic and therapeutic potentials of molecular profiling. Head Neck. 2024 Oct; 46 (10):E84-E90 Epub 2024 July 20
    View PubMed
22. Suleiman R, McGarrah P, Baral B, Owen D, Vera Aguilera J, Halfdanarson TR, Price KA, Fuentes Bayne HE. Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer Rep (Hoboken). 2024 Oct; 7 (10):e70023
    View PubMed
23. Kloeber JA, Ebner DK, Jethwa KR, Merrell KW, Halfdanarson TR, Callaghan CM. Proton Stereotactic Body Radiotherapy for Liver Metastases From Malignant Pancreatic Insulinoma. JCEM Case Rep. 2024 Oct; 2(10):luae175. Epub 2024 Sep 27.
    View PubMed
24. Fuentes Bayne HE, Kasi PM, Ma L, Hart LL, Wong J, Spigel DR, Schnabel CA, Reeves JA, Halfdanarson TR, Treuner K, Greco FA. Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary. JCO Precis Oncol. 2024 Sep; 8:e2400191
    View PubMed
25. Parmar C, Abi Mosleh K, Aeschbacher P, Halfdanarson TR, McKenzie TJ, Rosenthal RJ, Ghanem OM, BRIDGE Study Group. The feasibility and outcomes of metabolic and bariatric surgery prior to neoplastic therapy. Surg Obes Relat Dis. 2024 Aug; 20 (8):717-728 Epub 2024 Mar 07
    View PubMed
26. Gudmundsdottir H, Fogliati A, Grotz TE, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Nagorney DM, Halfdanarson TR, Cleary SP, Starlinger P. Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum. Ann Surg Oncol. 2024 Aug; 31 (8):5370-5376 Epub 2024 Apr 30
    View PubMed
27. Violante T, Murphy B, Ferrari D, Graham RP, Navin P, Merchea A, Larson DW, Dozois EJ, Halfdanarson TR, Perry WR. ASO Visual Abstract: Presacral Neuroendocrine Neoplasms: A Multi-site Review of Surgical Outcomes. Ann Surg Oncol. 2024 Aug; 31 (8):5322-5323
    View PubMed
28. Ammann M, Gudmundsdottir H, Hackl H, Antwi SKA, Santol J, Habermann EB, Thiels CA, Warner SG, Truty MJ, Kendrick ML, Smoot RL, Nagorney DM, Cleary SP, Halfdanarson TR, Starlinger PP. Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy. Ann Surg Oncol. 2024 Aug; 31 (8):4931-4941 Epub 2024 May 08
    View PubMed
29. Violante T, Dozois EJ, Halfdanarson TR, Perry WRG. ASO Author Reflections: Presacral Neuroendocrine Neoplasms-Insights into a Rare Disease. Ann Surg Oncol. 2024 Aug; 31 (8):5228-5229 Epub 2024 May 18
    View PubMed
30. Carlson DM, Abdelrahman AM, Adjei Antwi SK, Tomlinson JL, Trivedi K, Karbhari A, Patnam Gopal Chetty N, Halfdanarson TR, Goenka AH, Truty MJ. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer. J Am Coll Surg. 2024 Jul 1; 239 (1):9-17 Epub 2024 Mar 06
    View PubMed
31. Violante T, Murphy B, Ferrari D, Graham RP, Navin P, Merchea A, Larson DW, Dozois EJ, Halfdanarson TR, Perry WR. Presacral Neuroendocrine Neoplasms: A Multi-site Review of Surgical Outcomes. Ann Surg Oncol. 2024 Jul; 31 (7):4551-4557 Epub 2024 Apr 28
    View PubMed
32. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024 Jul-Aug; 74 (4):359-367 Epub 2024 Apr 29
    View PubMed
33. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D, all the NETTER-2 Trial Investigators. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29; 403 (10446):2807-2817 Epub 2024 June 05
    View PubMed
34. Mangioris G, Halfdanarson TR, Lennon VA, Chang BK, Dubey D, Dyck PJB, Flanagan EP, McKeon A, Mills JR, Pittock SJ, Zekeridou A. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles. Eur J Neurol. 2024 Jun; 31 (6):e16273 Epub 2024 Mar 11
    View PubMed
35. Kusne Y, Lasho T, Finke C, Elsabbagh Z, McCue S, Hobday T, Starr J, Bekaii-Saab T, Halfdanarson TR, Patnaik MM, Ou FS, Sonbol MB. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. JCO Precis Oncol. 2024 Jun; 8:e2400143
    View PubMed
36. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
37. Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, Sonbol MB, Ticku J, Jin Z, Taieb J, Sinicrope FA. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. Eur J Cancer. 2024 Jan; 196:113433 Epub 2023 Nov 10
    View PubMed
38. Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O. Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. 2024; 14(6):2367-2378. Epub 2024 Mar 25.
    View PubMed
39. Sada A, Ramachandran D, Oberoi M, Habermann EB, Lyden ML, Dy BM, Foster TR, Halfdanarson TR, Levy MJ, Vella A, McKenzie TJ. Ethanol Ablation for Benign Insulinoma: Intraoperative and Endoscopic Approaches. J Surg Res. 2024 Jan; 293:663-669 Epub 2023 Oct 13
    View PubMed
40. Belge Bilgin G, Bilgin C, Childs DS, Orme JJ, Burkett BJ, Packard AT, Johnson DR, Thorpe MP, Riaz IB, Halfdanarson TR, Johnson GB, Sartor O, Kendi AT. Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer (177)Lu-PSMA-617 therapy. Front Oncol. 2024; 14:1386718 Epub 2024 July 12
    View PubMed
41. Jorgenson LC, Torbenson MS, Halfdanarson TR, Kankeu Fonkoua LA, Tran NH, Roberts LR, Smoot RL, Goenka AH, Thompson SM. Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes. Front Nucl Med. 2024; 4:1480471 Epub 2024 Nov 27
    View PubMed
42. Zhang C, Gudmundsdottir H, Takahashi H, Day C, Glasgow A, Wasif N, Starlinger P, Warner S, Grotz T, Smoot R, Truty M, Cleary S, Kendrick M, Nagorney D, Navin P, Halfdanarson TR, Thiels C. Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection. J Surg Oncol. 2023 Dec; 128 (7):1072-1079 Epub 2023 Aug 02
    View PubMed
43. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023 Nov 10; 41 (32):5049-5067 Epub 2023 Sept 29
    View PubMed
44. Halfdanarson TR, Mallak N, Paulson S, Chandrasekharan C, Natwa M, Kendi AT, Kennecke HF. Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy. Cancers (Basel). 2023 Oct 2; 15 (19) Epub 2023 Oct 02
    View PubMed
45. Andreatos N, McGarrah PW, Sonbol MB, Starr JS, Capdevila J, Sorbye H, Halfdanarson TR. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. Curr Oncol Rep. 2023 Oct; 25(10):1127-1139. Epub 2023 Aug 22.
    View PubMed
46. Samhouri BF, Halfdanarson TR, Koo CW, McCarthy C, Yi ES, Thomas CF, Ryu JH. DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition. Endocr Relat Cancer. 2023 Oct 1; 30 (10) Epub 2023 Aug 16
    View PubMed
47. Pathak S, Starr JS, Halfdanarson T, Sonbol MB. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. 2023 Sep-Nov; 18 (5):377-385 Epub 2023 July 19
    View PubMed
48. Mosalem O, Sonbol MB, Halfdanarson TR, Starr JS. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms. Best Pract Res Clin Endocrinol Metab. 2023 Sep; 37 (5):101796 Epub 2023 June 28
    View PubMed
49. Leiting JL, Hernandez MC, Bergquist JR, Yonkus JA, Abdelrahman AM, Torbenson MS, Tran NH, Halfdanarson TR, Graham RP, Smoot RL, Truty MJ. Therapeutic Efficacy of Temsirolimus in a Patient-derived Model of Metastatic Fibrolamellar Hepatocellular Carcinoma. In Vivo. 2023 Sep-Oct; 37 (5):1940-1950
    View PubMed
50. Algarin-Perneth S, Suleiman R, Abeykoon JP, Halfdanarson T, Fuentes-Bayne HE, Yi JE, Peikert T, McGarrah PW. Deep and Repeated Response to Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2-Amplified Large-Cell Neuroendocrine Carcinoma With Brain Metastases: A Case Report. JCO Precis Oncol. 2023 Sep; 7:e2300242.
    View PubMed
51. Navin PJ, Ehman EC, Liu JB, Halfdanarson TR, Gupta A, Laghi A, Yoo DC, Carucci LR, Schima W, Sheedy SP. Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2023 Sep; 221 (3):289-301 Epub 2023 Apr 19
    View PubMed
52. Wang Y, Ayoub C, Yang AF, Sonbol MB, Butterfield R, Halfdanarson TR, Arsanjani R, Zhu W, Yang M. Gastroenteropancreatic Neuroendocrine Tumor Metastasis to the Heart: Evaluation of Imaging Manifestations. Curr Probl Diagn Radiol. 2023 Sep-Oct; 52 (5):340-345 Epub 2022 Nov 17
    View PubMed
53. Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, Crago A, Wise-Draper T, Balanchivadze N, Hwang C, Fecher LA, Gomez CG, Hayes-Lattin B, Glover MJ, Shah SA, Gopalakrishnan D, Griffiths EA, Kwon DH, Koshkin VS, Mahmood S, Bashir B, Nonato T, Razavi P, McKay RR, Nagaraj G, Oligino E, Puc M, Tregubenko P, Wulff-Burchfield EM, Xie Z, Halfdanarson TR, Farmakiotis D, Klein EJ, Robilotti EV, Riely GJ, Durand JB, Hayek SS, Kondapalli L, Berg S, O'Connor TE, Bilen MA, Castellano C, Accordino MK, Sibel B, Weissmann LB, Jani C, Flora DB, Rudski L, Dutra MS, Nathaniel B, Ruiz-Garcia E, Vilar-Compte D, Gupta S, Morgans A, Nohria A, COVID-19 and Cancer Consortium. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Transl Oncol. 2023 Aug; 34:101709 Epub 2023 June 02
    View PubMed
54. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023 Aug 1; 30 (8) Epub 2023 July 11
    View PubMed
55. Gudmundsdottir H, Habermann EB, Vierkant RA, Starlinger P, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Halfdanarson TR, Nagorney DM, Cleary SP. Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients. Ann Surg Oncol. 2023 Aug; 30 (8):4840-4851 Epub 2023 May 19
    View PubMed
56. Mukherjee S, Korfiatis P, Khasawneh H, Rajamohan N, Patra A, Suman G, Singh A, Thakkar J, Patnam NG, Trivedi KH, Karbhari A, Chari ST, Truty MJ, Halfdanarson TR, Bolan CW, Sandrasegaran K, Majumder S, Goenka AH. Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs. Pancreatology. 2023 Aug; 23 (5):522-529 Epub 2023 May 26
    View PubMed
57. Gudmundsdottir H, Halfdanarson TR, Nagorney DM, Cleary SP. ASO Author Reflections: Long-Term Outcomes after Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2023 Aug; 30 (8):4852-4853 Epub 2023 Mar 20
    View PubMed
58. Diamantopoulos LN, Kalligeros M, Halfdanarson TR, Diamantis N, Toumpanakis C. Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies. Biology (Basel). 2023 Jul 30; 12 (8) Epub 2023 July 30
    View PubMed
59. Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted Alpha-Particle Therapy: A Review of Current Trials. Int J Mol Sci. 2023 Jul 19; 24(14).
    View PubMed
60. Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoglu K, Pandey MK, Packard AT, Halfdanarson TR, Hruska CB, Johnson GB, Kendi AT. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023 Jul; 5 (4):e220157
    View PubMed
61. Ensign SF, Agarwal M, Klanderman M, Badawy M, Halfdanarson TR, Johnson DR, Sonbol MB, Kendi AT. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions. Nucl Med Commun. 2023 Jul 1; 44 (7):663-670 Epub 2023 May 08
    View PubMed
62. Naraev BG, Mailman J, Halfdanarson TR, Soares HP, Mittra ES, Hallet J. Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Anticancer Ther. 2023 Jun; 23 (6):601-615 Epub 2023 May 15
    View PubMed
63. Sada A, McKenzie TJ, Vella A, Levy MJ, Halfdanarson TR. Interventional vs surgical procedures in localized/nonmetastatic insulinomas (ablation vs surgery). Endocr Relat Cancer. 2023 Jun 1; 30 (6) Epub 2023 May 02
    View PubMed
64. Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, Pusceddu S, Prinzi N, Lombardi Stocchetti B, Grozinsky-Glasberg S, Gross DJ, Walter T, Robelin P, Lombard-Bohas C, Frassoni S, Bagnardi V, Antonuzzo L, Sparano C, Massironi S, Gelsomino F, Bongiovanni A, Ranallo N, Tafuto S, Rossi M, Cives M, Rasul Kakil I, Hamid H, Chirco A, Squadroni M, La Salvia A, Hernando J, Hofland J, Koumarianou A, Boselli S, Tamayo D, Mazzon C, Rubino M, Spada F. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study. Endocr Relat Cancer. 2023 Jun 1; 30 (6) Epub 2023 Apr 26
    View PubMed
65. Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clin Genitourin Cancer. 2023 Jun; 21 (3):403-414.e5 Epub 2023 Mar 17
    View PubMed
66. Gococo-Benore DA, Kuhlman J, Parent EE, Sharma A, Accurso J, Yang M, Kendi AT, Johnson G, Sonbol MB, Hobday T, Halfdanarson TR, Starr J. Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden. J Nucl Med. 2023 Jun; 64 (6):880-884 Epub 2023 Apr 20
    View PubMed
67. Gile JJ, McGarrah PW, Leventakos K, Sonbol MB, Starr JS, Eiring RA, Hobday TJ, Halfdanarson TR. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas. J Neuroendocrinol. 2023 May; 35 (5):e13283 Epub 2023 May 25
    View PubMed
68. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh). 2023 Apr; 7 (4):e2101319 Epub 2022 Mar 27
    View PubMed
69. Torbenson M, Venkatesh SK, Halfdanarson TR, Navin PJ, Kamath P, Erickson LA. Primary neuroendocrine tumors and primary neuroendocrine carcinomas of the liver: a proposal for a multidiscipline definition. Hum Pathol. 2023 Feb; 132:77-88 Epub 2022 July 06
    View PubMed
70. Saberzadeh-Ardestani B, Jones JC, Hubbard JM, McWilliams RR, Halfdanarson TR, Shi Q, Sonbol MB, Ticku J, Jin Z, Sinicrope FA. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. JAMA Netw Open. 2023 Feb 1; 6 (2):e230400 Epub 2023 Feb 01
    View PubMed
71. Abdelrahman AM, Yin J, Alva-Ruiz R, Yonkus JA, Leiting JL, Lynch IT, Fogliati A, Campbell NA, Carlson DM, Roberts LR, Gores GJ, Smoot RL, Graham RP, Halfdanarson TR, Truty MJ. Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States. Cancers (Basel). 2023 Jan 30; 15 (3)
    View PubMed
72. Eads JR, Halfdanarson TR, Asmis T, Belizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Expert consensus practice recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-Related Cancer. 2023; 30 (8):e220206
    
73. Alheraki SZ, Almquist DR, Starr JS, Halfdanarson TR, Sonbol MB. Treatment landscape of advanced high-grade neuroendocrine neoplasms. Clin Adv Hematol Oncol. 2023 Jan; 21 (1):16-26
    View PubMed
74. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM, COVID-19 and Cancer Consortium. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncol. 2023 Jan 01; 9(1):128-134.
    View PubMed
75. Clapp B, Portela R, Sharma I, Nakanishi H, Marrero K, Schauer P, Halfdanarson TR, Abu Dayyeh B, Kendrick M, Ghanem OM. Risk of non-hormonal cancer after bariatric surgery: meta-analysis of retrospective observational studies. Br J Surg. 2022 Dec 13; 110 (1):24-33
    View PubMed
76. Rajamohan N, Khasawneh H, Singh A, Suman G, Johnson GB, Majumder S, Halfdanarson TR, Goenka AH. PET/CT and PET/MRI in neuroendocrine neoplasms. Abdom Radiol (NY). 2022 Dec; 47 (12):4058-4072 Epub 2022 Apr 15
    View PubMed
77. Sada A, Habermann EB, Szabo Yamashita T, Thompson GB, Lyden ML, Foster TR, Dy BM, Halfdanarson TR, Vella A, McKenzie TJ. Comparison Between Sporadic and Multiple Endocrine Neoplasia Type 1-Associated Insulinoma. J Am Coll Surg. 2022 Nov 1; 235 (5):756-763 Epub 2022 Oct 17
    View PubMed
78. Gudmundsdottir H, Pery R, Graham RP, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Halfdanarson TR, Habermann EB, Nagorney DM, Cleary SP. Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2022 Oct; 29 (11):6949-6957 Epub 2022 June 22
    View PubMed
79. Gudmundsdottir H, Halfdanarson TR, Cleary SP. ASO Author Reflections: Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors-A Single Operation is Feasible in Most Patients. Ann Surg Oncol 2022 Oct; 29 (11):6958-6959 Epub 2022 July 03
    View PubMed
80. Marshall AL, Halfdanarson TR, Alkhateeb H, Hobday T. Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources. J Cancer Educ. 2022 Oct; 37 (5):1385-1388 Epub 2021 Jan 30
    View PubMed
81. Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, Merrell KW, Thiels CA, Hallemeier CL, Warner SG, Haddock MG, Grotz TE, Tran NH, Smoot RL, Ma WW, Cleary SP, McWilliams RR, Nagorney DM, Halfdanarson TR, Kendrick ML, Truty MJ. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. J Natl Compr Canc Netw. 2022 Sep; 20 (9):1023-1032.e3
    View PubMed
82. Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, Cleary SP, Hobday T, Halfdanarson TR. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist. 2022 Jul 5; 27 (7):573-578
    View PubMed
83. Halfdanarson TR, Foster NR, Kim GP, Haddock MG, Dakhil SR, Behrens RJ, Alberts SR. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. Oncologist. 2022 Jul 5; 27 (7):534-e546
    View PubMed
84. Gudmundsdottir H, Tomlinson JL, Graham RP, Thiels CA, Warner SG, Smoot RL, Kendrick ML, Nagorney DM, Halfdanarson TR, Habermann EB, Truty MJ, Cleary SP. Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasms. HPB (Oxford). 2022 Jul; 24 (7):1186-1193 Epub 2021 Dec 31
    View PubMed
85. Khanna L, Halfdanarson TR, Sonbol MB, Eiring R, Prond T, Camilleri M. Bile Acid Malabsorption in Patients with Neuroendocrine Tumors. Dig Dis Sci. 2022 Jun; 67 (6):2517-2525 Epub 2021 Aug 07
    View PubMed
86. Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol. 2022 May; 29 (5):3072-3084 Epub 2022 Feb 14
    View PubMed
87. Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, Chung KY, Cliby WA, Dorigo O, Eisen DB, Fujisawa Y, Golda N, Halfdanarson TR, Iavazzo C, Jiang SIB, Kanitakis J, Khan A, Kim JYS, Kuzel TM, Lawrence N, Leitao MM Jr, MacLean AB, Maher IA, Mittal BB, Nehal KS, Ozog DM, Pettaway CA, Ross JS, Rossi AM, Servaes S, Solomon MJ, Thomas VD, Tolia M, Voelzke BB, Waldman A, Wong MK, Zhou Y, Arai N, Brackett A, Ibrahim SA, Kang BY, Poon E, Alam M. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncol. 2022 Apr 1; 8 (4):618-628
    View PubMed
88. Alva-Ruiz R, Yohanathan L, Yonkus JA, Abdelrahman AM, Gregory LA, Halfdanarson TR, Mahipal A, McWilliams RR, Ma WW, Hallemeier CL, Graham RP, Grotz TE, Smoot RL, Cleary SP, Nagorney DM, Kendrick ML, Truty MJ. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2022 Mar; 29 (3):1579-1591 Epub 2021 Nov 01
    View PubMed
89. Gococo-Benore DA, Parent E, Sharma A, Accurso J, Yang M, Kendi AT, Sonbol B, Halfdanarson TR, Starr JS. Hepatotoxicity from peptide receptor radionuclide therapy (prrt) in neuroendocrine tumors (nets) patients with very high liver tumor burden. Pancreas. 2022; 51(3):E47.
    
90. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
91. Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1; 5 (2):e2149040 Epub 2022 Feb 01
    View PubMed
92. Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A, Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer. 2022 Feb 1; 128 (3):435-446 Epub 2021 Nov 04
    View PubMed
93. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C, COVID-19 and Cancer Consortium (CCC19). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Netw Open. 2022 Jan 4; 5 (1):e2142046 Epub 2022 Jan 04
    View PubMed
94. Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, Spada F. Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252]. Eur J Cancer. 2022 Jan; 160:289-290 Epub 2021 Oct 21
    View PubMed
95. Capdevila J, Ducreux M, Garcia Carbonero R, Grande E, Halfdanarson T, Pavel M, Tafuto S, Welin S, Valenti V, Salazar R. Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112 (12):1155-1167 Epub 2022 May 10
    View PubMed
96. Majumder S, Halfdanarson TR, Berger CK, Foote PH, Cao X, McGlinch MC, Gysbers BJ, de La Fuente J, Robran MJ, Doering KA, Burger KN, Bamlet WE, Oberg AL, Mahoney DW, Graham RP, Taylor WR, Petersen GM, Kisiel JB. Discovery and Validation of Methylated DNA Markers From Pancreatic Neuroendocrine Tumors. Gastro Hep Adv. 2022; 1 (3):409-416 Epub 2022 Apr 02
    View PubMed
97. Gudmundsdottir H, Graham RP, Sonbol MB, Smoot RL, Truty MJ, Kendrick ML, Nagorney DM, Habermann EB, Halfdanarson TR, Cleary SP. Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors. J Surg Oncol. 2021 Dec; 124 (7):1077-1084 Epub 2021 July 26
    View PubMed
98. Sandhya Manohar, Panagiotis Kompotiatis, Thorvardur R Halfdanarson, Timothy J Hobday, Matthew Thorpe, Geoffrey B Johnson, Ayse Tuba Kendi, Nelson Leung.. 177Lu-dotatate use in chronic kidney disease patients: A single center experience Journal of Onco-Nephrology. 2021; 5(3):162-171.
    
99. Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist. 2021 Nov; 26 (11):950-955 Epub 2021 Aug 21
    View PubMed
100. Zhu M, Sorenson KR, Liu R, Gould Rothberg BE, Halfdanarson TR. Biomarkers for prognosis in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2021 Oct 19; 28 (12):773-782
     View PubMed
101. Gits HC, Tang AH, Harmsen WS, Bamlet WR, Graham RP, Petersen GM, Smyrk TC, Mahipal A, Kowalchuk RO, Ashman JB, Rule WG, Owen D, Neben Wittich MA, McWilliams RR, Halfdanarson T, Ma WW, Sio TT, Cleary SP, Truty MJ, Haddock MG, Hallemeier CL, Merrell KW. Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. J Gastrointest Oncol. 2021 Oct; 12 (5):2275-2286
     View PubMed
102. Tella SH, Starr JS, Kommalapati A, Sonbol MB, Halfdanarson TR. Management of well-differentiated neuroendocrine tumors. Clin Adv Hematol Oncol. 2021 Sep; 19 (9):582-593
     View PubMed
103. Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, Spada F. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. Eur J Cancer. 2021 Sep; 154:246-252 Epub 2021 June 30
     View PubMed
104. Pritchett JC, Borah BJ, Desai AP, Xie Z, Saliba AN, Leventakos K, Coffey JD, Pearson KK, Speicher LL, Orenstein R, Virk A, Ganesh R, Paludo J, Halfdanarson TR, Haddad TC. Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncol Pract. 2021 Sep; 17 (9):e1293-e1302 Epub 2021 June 04
     View PubMed
105. Xie Z, Saliba AN, Abeykoon J, Majeed U, Almquist DR, Wiedmeier-Nutor JE, Bezerra E, Andrade-Gonzalez X, Hickman A, Sorenson K, Rakshit S, Wee C, Tella SH, Kommalapati A, Abdallah N, Pritchett J, De Andrade M, Uprety D, Badley A, Manochakian R, Ailawadhi S, Bryce AH, Hubbard JM, Gangat N, Thompson CA, Witzig TE, McWilliams RR, Leventakos K, Halfdanarson TR. Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncol Pract. 2021 Sep; 17 (9):e1382-e1393 Epub 2021 June 14
     View PubMed
106. Panda A, Garg I, Truty MJ, Kline TL, Johnson MP, Ehman EC, Suman G, Anaam DA, Kemp BJ, Johnson GB, Halfdanarson TR, Venkatesh SK, Fidler JL, Goenka AH. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. AJR Am J Roentgenol. 2021 Sep; 217 (3):730-740 Epub 2020 Oct 21
     View PubMed
107. Wee CE, Dundar A, Eiring RA, Badawy M, Hobday TJ, Kendi AT, Packard AT, Halfdanarson TR. Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. J Nucl Med 2021 Sep 1; 62 (9):1320 Epub 2021 Mar 19
     View PubMed
108. Ueberroth BE, Liu AJ, Graham RP, Bekaii-Saab TS, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. Pancreas. 2021 Aug 1; 50 (7):952-956
     View PubMed
109. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Jul 28; 19 (7):839-868 Epub 2021 July 28
     View PubMed
110. Yonkus JA, Bergquist JR, Alva-Ruiz R, Ivanics T, Habermann EB, Abdelrahman AM, Grotz TE, Cleary SP, Smoot RL, Nagorney DM, Kendrick ML, Halfdanarson TR, Truty MJ. A national database analysis of acinar cell carcinoma of the pancreas, a histologically, epidemiologically, and biologically distinct entity increasing in incidence Annals of Pancreatic Cancer. 2021 Jul; 4:A105
     
111. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 Jun; 32 (6):787-800 Epub 2021 Mar 19
     View PubMed
112. Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, Bekaii-Saab TS, Halfdanarson TR, Sonbol MB. Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options. Clin Colorectal Cancer. 2021 Jun; 20 (2):e139-e149 Epub 2020 Dec 17
     View PubMed
113. Jethwa KR, Day CN, Sandhyavenu H, Gonuguntla K, Harmsen WS, Breen WG, Routman DM, Garda AE, Hubbard JM, Halfdanarson TR, Neben-Wittich MA, Merrell KW, Hallemeier CL, Haddock MG. Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. Clin Transl Radiat Oncol. 2021 May; 28:17-23 Epub 2021 Feb 23
     View PubMed
114. Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist. 2021 May; 26 (5):383-388 Epub 2021 Feb 08
     View PubMed
115. Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel). 2021 Apr 7; 13 (8) Epub 2021 Apr 07
     View PubMed
116. Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas. 2021 Apr 1; 50 (4):500-505
     View PubMed
117. Durani U, Asante D, Heien HC, Thompson CA, Halfdanarson T, Sangaralingham L, Peethambaram P, Quevedo FJ, Villasboas JC, Go RS. Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations. JCO Oncol Pract. 2021 Apr; 17(4):e490-e496. Epub 2020 Oct 23.
     View PubMed
118. Smith CJ, Bekaii-Saab TS, Cook KD, Eiring RA, Halfdanarson TR, Hanna M, Jin Z, Jochum JA, Ma WW, Mitchell JL, Pitot HC, Jatoi A. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. Pancreatology. 2021 Mar; 21 (2):379-383 Epub 2020 Oct 18
     View PubMed
119. Sohail S, Zuk V, Halfdanarson T, Chan D, Pattison S, Vasdev R, Law C, Hallet J. The Quality of Online Information for an Uncommon Malignancy-Neuroendocrine Tumours (NETs). Curr Oncol. 2021 Feb 8; 28 (1):842-846 Epub 2021 Feb 08
     View PubMed
120. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, Mahipal A, McWilliams RR, Halfdanarson TR, Grothey AF. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021 Feb 1; 273 (2):341-349
     View PubMed
121. Sada A, Yamashita TS, Glasgow AE, Habermann EB, Thompson GB, Lyden ML, Dy BM, Halfdanarson TR, Vella A, McKenzie TJ. Comparison of benign and malignant insulinoma. Am J Surg. 2021 Feb; 221 (2):437-447 Epub 2020 Aug 16
     View PubMed
122. Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to (177)Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology. 2021 Feb; 298 (2):261-274 Epub 2020 Nov 24
     View PubMed
123. Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M, Goudet P, Halfdanarson TR, Ito T, Jensen RT, Larghi A, Lee L, Oberg K, Pavel M, Perren A, Sadowski SM, Tonelli F, Triponez F, Valk GD, O'Toole D, Scott-Coombes D, Thakker RV, Thompson GB, Treglia G, Wiedenmann B. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology. 2021; 111 (7):609-630 Epub 2020 Sept 24
     View PubMed
124. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
     View PubMed
125. Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol. 2021; 11:651119 Epub 2021 May 11
     View PubMed
126. Sonbol MB, Saad AM, Gonzalez-Velez M, Starr J, Halfdanarson TR. Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis. Pancreas. 2021 Jan 1; 50 (1):47-53
     View PubMed
127. Almquist DR, Sonbol MB, Ross HJ, Kosiorek H, Jaroszewski D, Halfdanarson T. Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Retrospective Analysis. Chest 2021 Jan; 159 (1):432-434 Epub 2020 Aug 14
     View PubMed
128. Jethwa KR, Sannapaneni S, Mullikin TC, Harmsen WS, Petersen MM, Antharam P, Laughlin B, Mahipal A, Halfdanarson TR, Merrell KW, Neben-Wittich M, Sio TT, Haddock MG, Hallemeier CL. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol. 2020 Dec; 11 (6):1408-1420
     View PubMed
129. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL, COVID-19 and Cancer Consortium. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020 Oct; 10 (10):1514-1527 Epub 2020 July 22
     View PubMed
130. Marshall AL, Halfdanarson TR, Nowakowski GS, Lacy MQ, Thompson CA, Hobday T. Holistic review for hematology-oncology fellowship applicants: A new paradigm? Am J Hematol 2020 Oct; 95 (10):1124-1126 Epub 2020 July 29
     View PubMed
131. Samhouri BF, Azadeh N, Halfdanarson TR, Yi ES, Ryu JH. Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. ERJ Open Res. 2020 Oct; 6 (4) Epub 2020 Nov 16
     View PubMed
132. Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas. 2020 Oct; 49 (9):1123-1130
     View PubMed
133. Liu AJ, Halfdanarson TR, Sonbol MB. Currarino Syndrome: A Rare Condition With Potential Connection to Neuroendocrine Tumors. Pancreas. 2020 Sep; 49 (8):1104-1108
     View PubMed
134. Uprety D, Halfdanarson TR, Molina JR, Leventakos K. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. Curr Treat Options Oncol. 2020 Aug 29; 21 (11):86
     View PubMed
135. Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, Nowakowski GS, Wang ML, Wang Y. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Aug 3; 3 (8):e2012534 Epub 2020 Aug 03
     View PubMed
136. Zhu M, Sonbol MB, Bassam Sonbol M, Halfdanarson T, Hobday T, Ahn D, Ma WW, Bekaii-Saab T. Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Oncologist. 2020 Aug; 25 (8):e1246-e1248 Epub 2020 July 01
     View PubMed
137. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 Aug; 49 (7):863-881
     View PubMed
138. McGarrah PW, Westin GFM, Hobday TJ, Scales JA, Ingimarsson JP, Leibovich BC, Halfdanarson TR. Renal Neuroendocrine Neoplasms: A Single-center Experience. Clin Genitourin Cancer. 2020 Aug; 18 (4):e343-e349 Epub 2019 Dec 05
     View PubMed
139. Venable ER, Kerr SE, Lopes MBS, Jones KA, Bellizzi AM, Mounajjed T, Raghunathan A, Hamidi O, Halfdanarson TR, Ryder M, Graham RP. Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases. Diagn Pathol. 2020 Jul 4; 15 (1):81 Epub 2020 July 04
     View PubMed
140. Al-Toubah T, Strosberg J, Halfdanarson TR, Oleinikov K, Gross DJ, Haider M, Sonbol MB, Almquist D, Grozinsky-Glasberg S. Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. Chest. 2020 Jul; 158 (1):401-405 Epub 2020 Feb 12
     View PubMed
141. Sonbol MB, Halfdanarson TR, Hilal T. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review. JAMA Oncol. 2020 Jul 1; 6 (7):1086-1092
     View PubMed
142. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20; 395 (10241):1907-1918 Epub 2020 May 28
     View PubMed
143. Kendi AT, Mailman JA, Naraev BG, Mercer DJ, Underwood JK, Halfdanarson TR. Patient Travel Concerns After Treatment with (177)Lu-DOTATATE. J Nucl Med. 2020 Apr; 61 (4):496-497 Epub 2020 Mar 13
     View PubMed
144. McGarrah PW, Leventakos K, Hobday TJ, Molina JR, Finnes HD, Westin GF, Halfdanarson TR. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma. Pancreas. 2020 Apr; 49 (4):529-533
     View PubMed
145. Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020; 13:3545-3555 Epub 2020 Apr 28
     View PubMed
146. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 Jan; 49 (1):1-33
     View PubMed
147. Xie H, Liu J, Yadav S, Keutgen XM, Hobday TJ, Strosberg JR, Halfdanarson TR. The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology. 2020; 110 (3-4):234-245 Epub 2019 May 24
     View PubMed
148. Durani U, Asante D, Halfdanarson T, Heien HC, Sangaralingham L, Thompson CA, Peethambaram P, Quevedo FJ, Go RS. Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population. J Natl Compr Canc Netw. 2019 Nov 1; 17 (11):1355-1361
     View PubMed
149. Reed CT, Duma N, Halfdanarson T, Buckner J. Primary neuroendocrine carcinoma of the brain. BMJ Case Rep. 2019 Sep 18; 12 (9) Epub 2019 Sept 18
     View PubMed
150. Huffman BM, Jin Z, Yadav S, Patel S, Nagorney DM, Truty MJ, McWilliams RR, Halfdanarson TR, Mahipal A. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma. Clin Colorectal Cancer. 2019 Sep; 18 (3):218-225 Epub 2019 May 15
     View PubMed
151. Naraev BG, Halland M, Halperin DM, Purvis AJ, O'Dorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas. 2019 Sep; 48 (8):961-972
     View PubMed
152. Sonbol MB, Halfdanarson TR. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Curr Treat Options Oncol. 2019 Aug 19; 20 (9):74
     View PubMed
153. Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. Therapy With (177)Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors. AJR Am J Roentgenol. 2019 Aug; 213 (2):309-317 Epub 2019 Apr 30
     View PubMed
154. Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019 Aug; 10 (4):674-687
     View PubMed
155. Nguyen A, Schaff HV, Abel MD, Luis SA, Lahr BD, Halfdanarson TR, Connolly HM. Improving outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg. 2019 Jul; 158 (1):99-107.e2 Epub 2018 Oct 03
     View PubMed
156. Panda A, Garg I, Johnson GB, Truty MJ, Halfdanarson TR, Goenka AH. Molecular radionuclide imaging of pancreatic neoplasms. Lancet Gastroenterol Hepatol. 2019 Jul; 4 (7):559-570
     View PubMed
157. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Jul 1; 5 (7):1008-1019
     View PubMed
158. Cho J, Chen JCY, Paludo J, Conboy EE, Lanpher BC, Alberts SR, Halfdanarson TR. Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. J Gastrointest Oncol. 2019 Jun; 10 (3):582-588
     View PubMed
159. Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist. 2019 May; 24 (5):589-e160 Epub 2019 Jan 24
     View PubMed
160. Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. Clin Lung Cancer. 2019 May; 20 (3):e376-e392 Epub 2019 Mar 01
     View PubMed
161. Chakrabarti S, Sara J, Lobo R, Eiring R, Finnes H, Mitchell J, Hartgers M, Okano A, Halfdanarson T, Grothey A. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clin Colorectal Cancer. 2019 Mar; 18 (1):52-57 Epub 2018 Oct 10
     View PubMed
162. Halfdanarson, Thorvardur. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer Annals of Surgery. 2019; 341-349.
     
163. Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist. 2019 Jan; 24 (1):96-102 Epub 2018 Nov 09
     View PubMed
164. Huffman BM, Westin G, Alsidawi S, Alberts SR, Nagorney DM, Halfdanarson TR, Mahipal A. Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas. Pancreas. 2018 Sep; 47 (8):1003-1007
     View PubMed
165. Ramage J, Naraev BG, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin Oncol. 2018 Aug; 45 (4):236-248 Epub 2018 Oct 24
     View PubMed
166. Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Semin Oncol. 2018 Aug; 45 (4):232-235 Epub 2018 Oct 11
     View PubMed
167. Briggler AM, Graham RP, Westin GF, Folpe AL, Jaroszewski DE, Okuno SH, Halfdanarson TR. Clinicopathologic features and outcomes of gastrointestinal stromal tumors arising from the esophagus and gastroesophageal junction. J Gastrointest Oncol. 2018 Aug; 9 (4):718-727
     View PubMed
168. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB 3rd, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 Jun; 16 (6):693-702
     View PubMed
169. Taylor G, Karlin N, Halfdanarson TR, Coppola K, Grothey A. Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clin Colorectal Cancer. 2018 Jun; 17 (2):e183-e187 Epub 2017 Nov 21
     View PubMed
170. Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol. 2018 Feb 20; 36 (6):600-608 Epub 2018 Jan 12
     View PubMed
171. Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD. Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clin Genitourin Cancer. 2017 Aug; 15 (4):e727-e734 Epub 2016 Dec 01
     View PubMed
172. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul; 46 (6):707-714
     View PubMed
173. Bendell J, Hubbard J, O'Neil BH, Jonker D, Starodub A, Peyton J, Pitot H, Halfdanarson T, Nadeau B, Zubkus J, Adesunloye B, Edenfield J, Li YZ, Li W, Grothey A, Borodyansky L, Li CJ. Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Ann Oncol. 2017 Jun; 28 Suppl 3:iii150-iii151
     View PubMed
174. Halfdanarson TR, Hogan WJ, Madsen BE. Emergencies in Hematology and Oncology. Mayo Clin Proc. 2017 Apr; 92 (4):609-641
     View PubMed
175. Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, Wijdicks EF, Goetz MP. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 2017 Mar 1; 28 (3):673-675
     View PubMed
176. Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Muller-Brand J, Howe JR, Halfdanarson TR. Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas. 2017 Feb; 46 (2):151-156
     View PubMed
177. Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017; 2017 Epub 2017 Aug 01
     View PubMed
178. Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH. Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Sci Rep. 2016 Dec 23; 6 (1):25
     View PubMed
179. Fitterer C, Berg Z, Halfdanarson TR, Vikram HR, Kusne S, Orenstein R, Seville MT, Blair JE. Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature. Mycopathologia. 2016 Dec; 181 (11-12):787-798 Epub 2016 Aug 04
     View PubMed
180. Padrnos L, Karlin N, Halfdanarson TR. Mayo Clinic Cancer Center Experience of Metastatic Extramammary Paget Disease 1998-2012. Rare Tumors. 2016 Nov 17; 8 (4):6804
     View PubMed
181. Chang JM, Katariya NN, Lam-Himlin DM, Haakinson DJ, Ramanathan RK, Halfdanarson TR, Borad MJ, Pannala R, Faigel D, Moss AA, Mathur AK. Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review. Case Rep Gastroenterol. 2016 Sep-Dec; 10 (3):605-612 Epub 2016 Oct 18
     View PubMed
182. Schroeder MC, Chapman CG, Nattinger MC, Halfdanarson TR, Abu-Hejleh T, Tien YY, Brooks JM. Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. BMC Health Serv Res. 2016 Jul 18; 16:274 Epub 2016 July 18
     View PubMed
183. Schroeder MC, Tien YY, Wright K, Halfdanarson TR, Abu-Hejleh T, Brooks JM. Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer. Lung Cancer. 2016 May; 95:28-34 Epub 2016 Feb 23
     View PubMed
184. Charlton ME, Hrabe JE, Wright KB, Schlichting JA, McDowell BD, Halfdanarson TR, Lin C, Stitzenberg KB, Cromwell JW. Hospital Characteristics Associated with Stage II/III Rectal Cancer Guideline Concordant Care: Analysis of Surveillance, Epidemiology and End Results-Medicare Data. J Gastrointest Surg. 2016 May; 20 (5):1002-11 Epub 2015 Dec 09
     View PubMed
185. Halfdanarson, Thorvardur. Circulating tumor markers in patients with neuroendocrine tumors – A clinical perspective Int J Endo Oncol. 2016; 2:89-99.
     
186. Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D, Boland PM. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015 Dec 22; 6 (41):43594-604
     View PubMed
187. Chen L, Nassar A, Kommineni VT, Zarka MA, Zhang J, Faigel D, Nguyen C, Halfdanarson TR, Pannala R. Endoscopic ultrasonography-guided fine-needle aspiration cytology of surgically confirmed cystic pancreatic neuroendocrine tumors: a Mayo Clinic experience. J Am Soc Cytopathol. 2015 Nov - Dec; 4 (6):335-343 Epub 2015 Apr 15
     View PubMed
188. Charlton ME, Stitzenberg KB, Lin C, Schlichting JA, Halfdanarson TR, Juarez GY, Pendergast JF, Chrischilles EA, Wallace RB. Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. J Oncol Pract. 2015 Jul; 11 (4):e476-86 Epub 2015 June 16
     View PubMed
189. Schlichting JA, Mengeling MA, Makki NM, Malhotra A, Halfdanarson TR, Klutts JS, Levy BT, Kaboli PJ, Charlton ME. Veterans' Continued Participation in an Annual Fecal Immunochemical Test Mailing Program for Colorectal Cancer Screening. J Am Board Fam Med. 2015 Jul-Aug; 28 (4):494-7
     View PubMed
190. Halfdanarson TR, Strosberg JR. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies. Curr Clin Pharmacol. 2015; 10 (4):305-10
     View PubMed
191. Kulke MH, Shah MH, Benson AB III, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW II, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J. Natl. Compr. Cancer Netw. 2015; 13(1):78-108.
     
192. Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2015 Jan; 19(1):152-60.
     View PubMed
193. Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2014 Nov; 18 (11):1929-35 Epub 2014 June 11
     View PubMed
194. Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, Petersen GM. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. Pancreas. 2014 Nov; 43 (8):1219-22
     View PubMed
195. Charlton ME, Mengeling MA, Halfdanarson TR, Makki NM, Malhotra A, Klutts JS, Levy BT, Kaboli PJ. Evaluation of a home-based colorectal cancer screening intervention in a rural state. J Rural Health. 2014 Sum; 30(3):322-32.
     View PubMed
196. Khan ML, Halfdanarson TR, Borad MJ. Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future Oncol. 2014 May; 10 (7):1255-75
     View PubMed
197. Halfdanarson TR. Cancer Care Outcomes Research and Surveillance Consortium (CanCORS). The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer American Journal of Clinical Oncology. 2014; 39(2):126-131.
     
198. Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O'Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014 Mar; 43 (2):219-25
     View PubMed
199. Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A, Halfdanarson TR. [Colorectal cancer - review]. Laeknabladid. 2014 Feb; 100(2):75-82.
     View PubMed
200. Schlichting JA, Mengeling MA, Makki NM, Malhotra A, Halfdanarson TR, Klutts JS, Levy BT, Kaboli PJ, Charlton ME. Increasing colorectal cancer screening in an overdue population: Participation and cost impacts of adding telephone calls to a fit mailing program. J Community Health. 2014; 39(2):239-47.
     View PubMed
201. Tallman BA, Lohnberg J, Yamada TH, Halfdanarson TR, Altmaier EM. Anticipating posttraumatic growth from cancer: Patients and collaterals experiences. J Psychosoc Oncol. 2014; 32(3):342-58.
     View PubMed
202. Charlton ME, Lin C, Jiang D, Stitzenberg KB, Halfdanarson TR, Pendergast JF, Chrischilles EA, Wallace RB. Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Am J Clin Oncol. 2013 Dec; 36(6):572-9.
     View PubMed
203. Halfdanarson TR, Pannala R. Incretins and risk of neoplasia. BMJ. 2013 Jun 10; 346:f3750 Epub 2013 June 10
     View PubMed
204. Leon-Ferre RA, Weiler CR, Halfdanarson TR. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab. Clin Adv Hematol Oncol. 2013 May; 11(5):317-9.
     View PubMed
205. Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas. 2013 Apr; 42 (3):411-21
     View PubMed
206. Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar; 71(3):765-75. Epub 2013 Feb 05.
     View PubMed
207. Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res. 2013; 2:105 Epub 2013 Apr 08
     View PubMed
208. Pagedar NA, Halfdanarson TR, Karnell LH, Hoffman HT, Funk GF. Upper aerodigestive tract cancer in patients with chronic lymphocytic leukemia: incidence, stage, and outcome. Arch Otolaryngol Head Neck Surg. 2012 Dec; 138(12):1171-5.
     View PubMed
209. Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012 Aug; 14(4):277-84.
     View PubMed
210. Leon-Ferre RA, Abu Hejleh TB, Halfdanarson TR. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. Clin Adv Hematol Oncol. 2012 Aug; 10(8):546-8.
     View PubMed
211. Abu Hejleh T, Deyoung BR, Engelman E, Deutsch JM, Zimmerman B, Halfdanarson TR, Berg DJ, Parekh KR, Lynch WR, Iannettoni MD, Bhatia S, Clamon G. Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol. 2012 May 15; 4(5):103-8.
     View PubMed
212. Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology. 2012; 83(3):117-27. Epub 2012 Jul 12.
     View PubMed
213. Charlton ME, Lin C, Jiang D, Stitzenerg KB, Halfdanarson TR, Pendergst JF, Chrischilles EA, Wallace RB. Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. American Journal of Clinical Oncology [Epub ahead of print]. 2012.
     
214. Naraev BG, Goodheart MJ, O'Dorisio TM, Halfdanarson TR. Small cell carcinoma of the uterine cervix: a single-center experience. Pancreas.2011;40:325-36.
     
215. Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ. Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol. 2010 Dec; 8 (12):1042-7 Epub 2010 Sept 17
     View PubMed
216. McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, de Andrade M, Reid-Lombardo K, Bamlet WR. Obesity adversely affects survival in pancreatic cancer patients. Cancer. 2010 Nov 1; 116 (21):5054-62
     View PubMed
217. O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010 Jul; 39(5):611-6.
     View PubMed
218. Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep. 2010 Jul; 12(4):247-52.
     View PubMed
219. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010 Jun; 199 (6):797-803
     View PubMed
220. Wehbe AM, Johannsson B, Raife TJ, Bleile M, Bell A, Curtis BR, Halfdanarson TR. Severe autoimmune neutropenia associated with acute autoimmune hepatitis. Int J Hematol. 2010 May; 91(4):673-8. Epub 2010 Apr 02.
     View PubMed
221. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J. 2010 Mar-Apr; 16(2):125-31.
     View PubMed
222. Tryggvason G, Sveinsson TE, Hjartarson H, Halfdanarson TR. [Head and neck squamous cell cancer]. Laeknabladid. 2009 Oct; 95(10):671-80.
     View PubMed
223. Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol. 2009 Feb; 43(2):162-4.
     View PubMed
224. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008 Oct; 19 (10):1727-33 Epub 2008 May 30
     View PubMed
225. Halfdanarson TR, Wang L, Bamlet WR, de Andrade, McWilliams RR, Cunningham JM, Petersen GM. Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2512-3.
     View PubMed
226. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008 Jun; 15 (2):409-27
     View PubMed
227. Halfdanarson TR, Kumar N, Li CY, Phyliky RL, Hogan WJ. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol. 2008 Jun; 80(6):523-31. Epub 2008 Feb 12.
     View PubMed
228. Halfdanarson TR, Thordardottir E, West CP, Jatoi A. Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. J Support Oncol. 2008 May-Jun; 6(5):234-7.
     View PubMed
229. Halfdanarson TR, Walker JA, Litzow MR, Hanson CA. Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis. Eur J Haematol. 2008 May; 80(5):448-51. Epub 2008 Jan 23.
     View PubMed
230. Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood. 2007 Jan 15; 109 (2):412-21 Epub 2006 Sept 14
     View PubMed
231. Halfdanarson TR, Jatoi A. Chocolate as a cough suppressant: rationale and justification for an upcoming clinical trial. Support Cancer Ther. 2007 Jan 1; 4 (2):119-22
     View PubMed
232. Halfdanarson, Jatoi. Theobromine, a Substance Intrinsic to Dark Chocolate, as a Cough Suppressant: Rationale and Justification for an Upcoming Clinical Trial Supportive Cancer Therapy. 2007; 119-122.
     
233. Batsis JA, Halfdanarson TR, Pitot H. Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice. Dig Liver Dis. 2006 Oct; 38(10):768-71. Epub 2005 Oct 19.
     View PubMed
234. Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc. 2006 Jun; 81(6):835-48.
     View PubMed
235. Dunn AS, Kaboli P, Halfdanarson TR, Chan H, Hubert R, Rosen S, White RH. Do patients followed in anticoagulation clinics for antiphospholipid syndrome meet criteria for the disorder? Thromb Haemost. 2005; 94:548-54.
     
236. Halfdanarson TR, Sigfusson A, Haraldsdottir V, Thornorsteinsson SB, Palsson R. [Severe adverse effects of quinine: Report of seven cases.]. Laeknabladid. 2002 Oct; 88(10):717-22.
     View PubMed
237. Halfdanarson TR, Thorstensen O, Palsson R. Necrotizing fasciitis of the chest wall, a case report. Icelandic Medical Journal. 1998; 84:643-6.